Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study

Abstract Background ROS1-rearranged lung cancers benefit from first-line crizotinib therapy; however, clinical and molecular factors that could affect crizotinib efficacy in ROS1-rearranged lung cancers are not yet well-elucidated. Our retrospective study aimed to compare the efficacy of chemotherap...

Full description

Bibliographic Details
Main Authors: Yongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Sai-Hong Ignatius Ou, Jiexia Zhang, Zhengbo Song, Nong Yang
Format: Article
Language:English
Published: BMC 2021-09-01
Series:BMC Medicine
Subjects:
ROS1 gene rearrangements
Crizotinib
Concomitant mutations
Progression associated efficacy
Online Access:https://doi.org/10.1186/s12916-021-02082-6

Internet

https://doi.org/10.1186/s12916-021-02082-6

Similar Items